2 news items
Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
TSBX
13 May 24
the limitations of first-generation bulk TIL that have demonstrated objective responses only in limited tumor types. Turnstone's most advanced program, TIDAL-01
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
TSBX
8 May 24
demonstrated objective responses only in limited tumor types. Turnstone's most advanced program, TIDAL-01, is currently being evaluated in multiple Phase
- Prev
- 1
- Next